Hemogenyx Pharmaceuticals (HEMO) Competitors GBX 373 +23.00 (+6.57%) As of 01/21/2025 11:40 AM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlines HEMO vs. BTG, ABC, ONT, GNS, ERGO, SLN, OXB, PRTC, HZD, and VRPShould you be buying Hemogenyx Pharmaceuticals stock or one of its competitors? The main competitors of Hemogenyx Pharmaceuticals include BTG (BTG), Abcam (ABC), Oxford Nanopore Technologies (ONT), Genus (GNS), Ergomed (ERGO), Silence Therapeutics (SLN), Oxford Biomedica (OXB), PureTech Health (PRTC), Horizon Discovery Group plc (HZD.L) (HZD), and Verona Pharma plc (VRP.L) (VRP). These companies are all part of the "biotechnology" industry. Hemogenyx Pharmaceuticals vs. BTG Abcam Oxford Nanopore Technologies Genus Ergomed Silence Therapeutics Oxford Biomedica PureTech Health Horizon Discovery Group plc (HZD.L) Verona Pharma plc (VRP.L) BTG (LON:BTG) and Hemogenyx Pharmaceuticals (LON:HEMO) are both mid-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, community ranking, risk, valuation, profitability, earnings, analyst recommendations and institutional ownership. Does the MarketBeat Community prefer BTG or HEMO? BTG received 564 more outperform votes than Hemogenyx Pharmaceuticals when rated by MarketBeat users. Likewise, 73.95% of users gave BTG an outperform vote while only 57.89% of users gave Hemogenyx Pharmaceuticals an outperform vote. CompanyUnderperformOutperformBTGOutperform Votes61973.95% Underperform Votes21826.05% Hemogenyx PharmaceuticalsOutperform Votes5557.89% Underperform Votes4042.11% Do institutionals and insiders hold more shares of BTG or HEMO? 0.8% of Hemogenyx Pharmaceuticals shares are owned by institutional investors. 10.7% of Hemogenyx Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Is BTG or HEMO more profitable? BTG's return on equity of 0.00% beat Hemogenyx Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets BTGN/A N/A N/A Hemogenyx Pharmaceuticals N/A -155.97%-37.79% Which has higher valuation and earnings, BTG or HEMO? BTG has higher revenue and earnings than Hemogenyx Pharmaceuticals. Hemogenyx Pharmaceuticals is trading at a lower price-to-earnings ratio than BTG, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBTG£914.10M0.00N/A£28.50N/AHemogenyx PharmaceuticalsN/AN/A-£5.18M-£0.01-37,300.00 Does the media refer more to BTG or HEMO? In the previous week, BTG had 1 more articles in the media than Hemogenyx Pharmaceuticals. MarketBeat recorded 1 mentions for BTG and 0 mentions for Hemogenyx Pharmaceuticals. BTG's average media sentiment score of 0.07 beat Hemogenyx Pharmaceuticals' score of 0.00 indicating that BTG is being referred to more favorably in the media. Company Overall Sentiment BTG Neutral Hemogenyx Pharmaceuticals Neutral SummaryBTG beats Hemogenyx Pharmaceuticals on 9 of the 11 factors compared between the two stocks. Get Hemogenyx Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for HEMO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart HEMO vs. The Competition Export to ExcelMetricHemogenyx PharmaceuticalsBiotechnology IndustryMedical SectorLON ExchangeMarket Cap£5.00B£177.42M£5.39B£2.04BDividend YieldN/A3.64%5.37%5.16%P/E Ratio-37,300.00131.1588.911,926.65Price / SalesN/A19,225.171,290.81384,006.48Price / Cash2.0513.0136.6029.21Price / BookN/A9.234.963.08Net Income-£5.18M-£20.89M£117.89M£183.60M7 Day Performance-2.86%0.14%1.68%1.24%1 Month Performance8.62%2.31%3.63%3.43%1 Year Performance13,533.04%126.91%26.16%43.35% Hemogenyx Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HEMOHemogenyx PharmaceuticalsN/AGBX 373+6.6%N/A+13,663.8%£5.00BN/A-37,300.0014BTGBTGN/AN/AN/AN/A£3.26B£914.10M29.474,690ABCAbcamN/AN/AN/AN/A£2.81B£350.40M20,433.331,650Gap UpHigh Trading VolumeONTOxford Nanopore Technologies2.4022 of 5 starsGBX 142.70+8.9%GBX 235.50+65.0%-3.8%£1.34B£167.75M-713.501,281GNSGenus1.313 of 5 starsGBX 1,480+0.1%GBX 2,150+45.3%-20.0%£970.44M£668.80M12,333.33480Negative NewsERGOErgomedN/AN/AN/AN/A£701.00M£152.09M4,641.386News CoverageSLNSilence TherapeuticsN/AN/AN/AN/A£480.35M£11.35M-11.01100High Trading VolumeOXBOxford Biomedica0.6574 of 5 starsGBX 410-0.2%GBX 433.33+5.7%+129.5%£431.98M£97.28M-284.72891PRTCPureTech Health1.5026 of 5 starsGBX 139.40-0.4%GBX 455+226.4%-27.0%£333.75M£3.33M-606.09300HZDHorizon Discovery Group plc (HZD.L)N/AN/AN/AN/A£302.98M£54.63M-33.55416VRPVerona Pharma plc (VRP.L)N/AN/AN/AN/A£228MN/A-1.6822Gap Up Related Companies and Tools Related Companies BTG Alternatives Abcam Alternatives Oxford Nanopore Technologies Alternatives Genus Alternatives Ergomed Alternatives Silence Therapeutics Alternatives Oxford Biomedica Alternatives PureTech Health Alternatives Horizon Discovery Group plc (HZD.L) Alternatives Verona Pharma plc (VRP.L) Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (LON:HEMO) was last updated on 1/22/2025 by MarketBeat.com Staff From Our PartnersBill Gates’ is about to mint millionaires (again) with Stargate.This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredDid You See Trump’s Manhattan Project Bombshell?This secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredTrump currency shock imminentTrump's Quiet $1.9 Trillion Move Against the Fed A small army of Americans, with Trump's support, has launc...Stansberry Research | SponsoredJanuary 29th - the next big trading catalyst to watch Mark your calendar for January 29th. Because on that day, I believe we could see a $2 Trillion shock INTO t...Timothy Sykes | SponsoredElon’s #1 AI Stock” SET TO SOARForget ChatGPT! Because Elon Musk's AI promises to be 100x more powerful.Behind the Markets | SponsoredDeFi Coin on Verge of Breakout!The blueprint for millionaires is here. Don't let this be the missed opportunity you regret for years. Crypto 101 Media | SponsoredI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hemogenyx Pharmaceuticals Plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Hemogenyx Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free HEMO Stock Alerts